Jennifer Raab

Jennifer Raab focuses her practice on the representation of life sciences companies in a wide range of complex strategic transactions, including collaboration agreements, license agreements, co-development and co-promotion agreements, option agreements and manufacturing agreements. She has expertise in both global transactions as well as territory-specific transactions.

Jennifer’s representative transactions include the representation of:

• Zai Lab in its exclusive collaboration and license agreement with argenx for the development and commercialization of efgartigimod in Greater China, including mainland China, Hong Kong, Taiwan and Macau.
• I-Mab Biopharma in its global license and collaboration agreement with AbbVie Ireland for the development and commercialization of lemzoparlimab, an innovative anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers, for a $180 million upfront payment, up to $1.76 billion in milestone payments, and tiered royalties.
• Sangamo in its collaboration and license agreement with Novartis to develop and commercialize gene regulation therapies to address three neurodevelopmental targets, including autism spectrum disorder (ASD) and other neurodevelopmental disorders, for a $75 million upfront payment, up to $720 million in milestone payments, and tiered royalties.
• Jacobio in its strategic collaboration with AbbVie Ireland to develop and commercialize SHP2 inhibitors, which target a key node in cancer and immune cells.
• Sangamo Therapeutics in its collaboration and license agreement with Biogen to develop and commercialize gene regulation therapies for Alzheimer’s, Parkinson’s, and other neurological diseases, for a $125 million upfront payment, $225 million equity payment, up to $2.37 billion in milestone payments, and tiered royalties.
• Jazz Pharmaceuticals in its exclusive license agreement with PharmaMar for lurbinectedin in the United States, for a $200 million upfront payment, up to $800 million in milestone payments, and tiered royalties.
• Cue Biopharma in its multi-target strategic collaboration with LG Chem Life Sciences to develop multiple Immuno-STAT biologics focused in the field of oncology, for a $5 million equity investment, up to $400 million in milestone payments, and tiered royalties.
• Jazz Pharmaceuticals in its collaboration and option agreement with ImmunoGen to develop and commercialize anti-body drug conjugate products used for cancer treatments, for a $75 million upfront payment, up to $100 million in development funding, along with an option exercise, potential milestone payments, and tiered royalties.